Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NeoGenomics Inc. (NEO)
:NEO
Holding NEO?
Track your performance easily
NEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.77 - $19.12
Previous CloseN/A
Volume108.49K
Average Volume (3M)686.41K
Market Cap
$2.39B
Enterprise Value$2.09B
Total Cash (Recent Filing)$12.53M
Total Debt (Recent Filing)$97.44M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Feb 25, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding128,360,870
10 Day Avg. Volume549,747
30 Day Avg. Volume686,407
Standard Deviation0.17
R-Squared0.14
Alpha-0.00939
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.66
Price to Cash Flow (P/CF)63.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue3.25
Enterprise Value/Gross Profit8.55
Enterprise Value/Ebitda5.18K
Forecast
1Y Price Target
$20.88Price Target Upside10.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
NeoGenomics News
PremiumCompany Announcements
NeoGenomics Reports Strong Q3 2024 Growth
PremiumCompany Announcements
NeoGenomics Reports Strong Q3 2024 Revenue GrowthBulls Say, Bears Say
Bulls Say
Margin ExpansionGross margin improved significantly due to revenue growth and increased operating leverage.
Revenue GrowthClinical Services revenue exceeded expectations due to improvements in both volume and revenue per test.
Strategic PositioningNeoGenomics Inc. is viewed as a one-stop oncology lab testing service provider with growth opportunities in NGS products and biopharma Dx services.
Bears Say
Business PerformancePharma Advanced Dx business was softer than expected, missing Street expectations by 10% due to an unimproved biotech/biopharma backdrop.
Revenue DeclineAdvanced Diagnostics saw a 10% decline year-over-year, driven by lower revenues from RaDaR, international site closures, and restructuring.
Stock PerformanceThe RaDaR injunction remains an overhang on the stock, affecting its performance.
---
Ownership Overview
1.13% Insiders
35.77% Mutual Funds
0.02% Other Institutional Investors
37.45% Public Companies and Individual Investors
NEO FAQ
What was NeoGenomics Inc.’s price range in the past 12 months?
NeoGenomics Inc. lowest stock price was $12.77 and its highest was $19.11 in the past 12 months.
What is NeoGenomics Inc.’s market cap?
NeoGenomics Inc.’s market cap is $2.39B.
When is NeoGenomics Inc.’s upcoming earnings report date?
NeoGenomics Inc.’s upcoming earnings report date is Feb 25, 2025 which is in 47 days.
How were NeoGenomics Inc.’s earnings last quarter?
Currently, no data Available
Is NeoGenomics Inc. overvalued?
According to Wall Street analysts NeoGenomics Inc.’s price is currently Undervalued.
Does NeoGenomics Inc. pay dividends?
NeoGenomics Inc. does not currently pay dividends.
What is NeoGenomics Inc.’s EPS estimate?
NeoGenomics Inc.’s EPS estimate is 0.03.
How many shares outstanding does NeoGenomics Inc. have?
NeoGenomics Inc. has 128,360,870 shares outstanding.
What happened to NeoGenomics Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NeoGenomics Inc.?
Currently, no hedge funds are holding shares in NEO
---
NeoGenomics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.88 (10.59% Upside)
$20.88 (10.59% Upside)
Crowd Wisdom
Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.87%
12-Months-Change
Fundamentals
Return on Equity
-8.38%
Trailing 12-Months
Asset Growth
-2.21%
Trailing 12-Months
Company Description
NeoGenomics Inc.
NeoGenomics, Inc. is a clinical laboratory, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the following two segments: Clinical and Pharma Services. The Clinical Services segment offers clinical cancer testing services to community-based pathologists. The Pharma Services segments supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. The Clinical Services Segment provides various clinical testing services to community-based pathology practices, hospital pathology labs and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment: provides comprehensive testing services in supports pharmaceutical clients' oncology programs from discovery to commercialization. Its services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
---
NEO Stock 12 Month Forecast
Average Price Target
$20.88
▲(10.59% Upside)
Technical Analysis
Best Analysts Covering NEO
1 Year
1 Year Success Rate
12/16 ratings generated profit
1 Year Average Return
+8.74%
assigned a buy rating 2 months ago
Copying Bruce Jackson's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +8.74% per trade.
---